EVENTIDE ASSET MANAGEMENT, LLC
Q2 2023 13F-HR Holdings
Net value change ($000)
+466,407
(8.6%)
New positions
16
Sold out positions
23
Turnover %
8.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ZNTL | 138,519 | 249.6% |
| GH | 99,558 | 226.5% |
| EXAS | 48,740 | 38.5% |
| LAD | 45,558 | 158.6% |
| CHINOOK THERAPEUTICS, INC. | 40,709 | 122.2% |
| MIRM | 40,028 | 80.9% |
| TOST | 36,199 | NEW |
| WDAY | 29,755 | 6626.9% |
| ImmunoGen, Inc. | 24,531 | NEW |
| XMTR | 24,122 | 55.5% |
Top Reduces (Value $000, Stocks/ETFs)
| Prometheus Biosciences, Inc. | -71,907 | -100.0% |
| MTD | -44,484 | -22.0% |
| DOCS | -37,357 | -22.0% |
| ENPH | -35,975 | -100.0% |
| ASND | -32,579 | -38.8% |
| VectivBio Holding AG | -31,611 | -100.0% |
| CCI | -31,459 | -100.0% |
| Seagen Inc. | -31,451 | -55.5% |
| VRSK | -24,776 | -64.2% |
| IMVT | -21,559 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|